Assignee: The Children's Medical Center Corporation

Location: Boston, MA
No. of patents: 122

Number	Title	Issue Date
8153806	Synthesis of 4-amino-thalidomide enantiomers The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(−)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibitin...	04/10/2012
8143283	Methods for treating blood-born tumors with thalidomide The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogene...	03/27/2012
7960525	Gene repair involving in vivo excision of targeting DNA Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. ...	06/14/2011
7867975	Therapeutic antiangiogenic endostatin compositions Endostatin compositions capable of inhibiting endothelial cell proliferation, inhibiting angiogenesis and causing tumor regression are described. Specifically, amino acid sequences of endostatin proteins and nucleic acid sequences coding for endostatin proteins are ...	01/11/2011
7812169	Method of synthesis of 4-amino-thalidomide enantiomers The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(−)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibitin...	10/12/2010
7655458	Nucleic acid molecules encoding endostatin protein and peptide fragments thereof An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease. ...	02/02/2010
7495089	Therapeutic antiangiogenic endostatin compositions Endostatin compositions capable of inhibiting endothelial cell proliferation, inhibiting angiogenesis and causing tumor regression are described. Specifically, amino acid sequences of endostatin proteins and nucleic acid sequences coding for endostatin proteins are ...	02/24/2009
7485439	Nucleic acids encoding plasminogen fragments and methods of use Nucleic acid sequence encoding kringle region fragment of plasminogen vectors comprising such nucleic acid, and methods of use of such nucleic acids, Ribonucleic and deoxyribonucleic acid sequence that encode for kringle region fragments are useful for gene therapy ...	02/03/2009
7470425	Population of undifferentiated neural, endocrine or neuroendocrine cells in a hydrogel support The invention features a method for generating new tissue by obtaining a liquid hydrogel-cell composition including a hydrogel and tissue precursor cells; delivering the liquid hydrogel-cell composition into a permeable, biocompatible support structure; and allowing...	12/30/2008
7427603	Method of enhancing proliferation and/or hematopoietic differentiation of stem cells The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood...	09/23/2008
7402725	WIP, a WASP-associated protein Described herein is a novel gene and its product, WIP, which associates with WASP. The subject invention relates to the isolated WIP gene or cDNA and transgenic mammals that have the WIP gene disrupted in their genome. Also the subject of this invention are methods ...	07/22/2008
RE40360	Methods for inhibition of angiogenesis with a composition comprising 3-hydroxythalidomide The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogene...	06/03/2008
7381848	Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa...	06/03/2008
7365159	Angiostatin protein The present invention provides plasminogen fragments containing kringle region domains having anti-angiogenic activity and termed angiostatin protein. The plasminogen fragments of the present invention may be used for the treatment of angiogenesis-dependent diseases...	04/29/2008
7291610	Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa...	11/06/2007
7285538	Gene repair involving in vivo excision of targeting DNA Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. ...	10/23/2007
7186409	Neural stem cells and use thereof for brain tumor therapy The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering gen...	03/06/2007
7179608	Therapeutic antiangiogenic compositions and methods An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease. ...	02/20/2007
7157556	Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use Disclosed are deglycosylated fragments of a kringle 1-3 region of plasminogen, nucleotides encoding deglycosylated kringle 1-3 region proteins and antibodies specific for deglycosylated kringle 1-3 region proteins. The compositions of the present invention have incr...	01/02/2007
7112602	Methods of treating undesired angiogenesis with 2-methyl-EM-138 The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The inv...	09/26/2006
7109187	Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa...	09/19/2006
7101979	Antibodies to antiangiogenic compositions and methods Antibody to endostatin protein that is an inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 18 kDa as determined by non-reduced gel electrophoresis, and approximately 20 kDa as determi...	09/05/2006
7081477	Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa...	07/25/2006
7071194	Method for improving respiratory function and inhibiting muscular degeneration The present invention provides a method for improving respiratory function and inhibiting muscular degeneration (e.g., dystrophy and atrophy). Alternative embodiments of the invention provide a method of inhibiting motor neuron apoptosis and the subsequent muscular ...	07/04/2006
7012070	Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa...	03/14/2006
6958226	Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins Novel packaging cell lines useful for generating viral accessory protein independent HIV-derived retroviral vector particles, methods of constructing such packaging cell lines and methods of using the viral accessory protein independent HIV-derived retroviral vector...	10/25/2005
6949511	Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen The present invention provides methods of inhibiting angiogenesis by increasing the concentration of kringle region fragments of plasminogen molecules in vivo. The methods of the present invention may be used for the treatment of angiogenesis-dependent diseases such...	09/27/2005
6930128	Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa...	08/16/2005
6927318	WIP, a WASP-associated protein Described herein is a novel gene and its product, WIP, which associates with WASP. The subject invention relates to the isolated WIP gene or cDNA and transgenic mammals that have the WIP gene disrupted in their genome. Also the subject of this invention are methods ...	08/09/2005
6908910	Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa...	06/21/2005
6764995	Endostatin protein and fragments thereof The present invention provides anti-angiogenic compositions, and more particularly provides endostatin protein fragments. The compositions of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer. ...	07/20/2004
6746865	Nucleic acids encoding for endostatin protein Nucleic acid sequences encoding for endostatin protein. Ribonucleic and deoxyribonucleic acid sequences that encode for endostatin protein are useful for gene therapy or recombinant expression for the treatment of angiogenesis-related diseases, specifically angiogen...	06/08/2004
6723694	Short peptides which selectively modulate intracellular signalling Disclosed are peptides which are peptide derivatives of the HJ loop of a protein tyrosine kinase. The peptides can modulate the activity of the protein tyrosine kinase. Also disclosed are methods of modulating the activity of a protein tyrosine kinase in a subject b...	04/20/2004
6723858	Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa...	04/20/2004
6680198	Engraftable human neural stem cells Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, olig...	01/20/2004
6673546	Genetic loci indicative of propensity for longevity and methods for identifying propensity for age-related disease This invention relates to genetic loci and methods for using polymorphic markers indicative of the propensity for longevity and the resistance to age-related disease. In particular, the invention defines a specified region of human chromosome 4 associated...	01/06/2004
6670321	Prevention and treatment for retinal ischemia and edema The claimed invention relates to methods of treating retinopathy, retinal ischemia and/or retinal edema comprising administering an integrin antagonist, a leukocyte adhesion inducing cytokine antagonist, a selectin antagonist or adhesion molecule antagoni...	12/30/2003
6635446	WIP, a WASP-associated protein Described herein is a novel gene and its product, WIP, which associates with WASP. The subject invention relates to the isolated WIP gene or cDNA (see FIGS. 1A-1B); nucleic acid probes, which can be fragments of the WIP gene or WIP cDNA or full-length; nu...	10/21/2003
6630448	Methods of inhibiting angiogenesis with endostatin protein Methods of inhibiting angiogenesis by administration of an isolated endostatin protein. Endostatin may be administered to individuals for treatment or repression of the growth of tumors, or administered to endothelial cells to inhibit their proliferation....	10/07/2003
6544758	Methods for expressing endostatin protein An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related dis...	04/08/2003

«First «Previous1 2 3 4 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: The Children's Medical Center Corporation